Research Analysts Issue Forecasts for Puma Biotechnology, Inc.’s FY2025 Earnings (NASDAQ:PBYI)

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Equities research analysts at Zacks Research dropped their FY2025 earnings per share (EPS) estimates for shares of Puma Biotechnology in a research report issued on Thursday, September 26th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of $0.19 for the year, down from their prior estimate of $0.22. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.25 per share.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The company had revenue of $47.10 million during the quarter, compared to analysts’ expectations of $43.99 million. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. During the same period last year, the business earned $0.05 EPS.

PBYI has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday, August 2nd. StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 13th.

Puma Biotechnology Stock Up 0.8 %

Puma Biotechnology stock opened at $2.58 on Monday. The company has a current ratio of 1.32, a quick ratio of 1.23 and a debt-to-equity ratio of 0.90. Puma Biotechnology has a 1-year low of $2.13 and a 1-year high of $7.73. The company has a fifty day simple moving average of $2.93 and a 200 day simple moving average of $3.82. The company has a market cap of $126.55 million, a P/E ratio of 7.82 and a beta of 1.09.

Hedge Funds Weigh In On Puma Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. boosted its holdings in shares of Puma Biotechnology by 8.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock worth $9,984,000 after buying an additional 246,264 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in Puma Biotechnology during the second quarter worth approximately $58,000. Affinity Asset Advisors LLC bought a new stake in shares of Puma Biotechnology during the second quarter worth approximately $815,000. Squarepoint Ops LLC grew its position in shares of Puma Biotechnology by 17.7% in the second quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock valued at $233,000 after purchasing an additional 10,757 shares during the last quarter. Finally, Great Point Partners LLC increased its stake in shares of Puma Biotechnology by 10.6% during the second quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock worth $4,846,000 after purchasing an additional 142,916 shares during the period. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 18,885 shares of the stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $3.27, for a total value of $61,753.95. Following the completion of the sale, the chief executive officer now owns 7,085,435 shares in the company, valued at $23,169,372.45. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Puma Biotechnology news, CEO Alan H. Auerbach sold 18,885 shares of the company’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $3.27, for a total value of $61,753.95. Following the sale, the chief executive officer now owns 7,085,435 shares in the company, valued at $23,169,372.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael Patrick Miller sold 23,358 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $3.49, for a total value of $81,519.42. Following the completion of the sale, the director now directly owns 47,000 shares of the company’s stock, valued at $164,030. The disclosure for this sale can be found here. Over the last three months, insiders have sold 82,263 shares of company stock worth $286,469. Insiders own 23.70% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.